Tusamitamab Ravtansine (SAR-408701)
CAS: 2254086-60-5
Description:
Tusamitamab ravtansine (SAR-408701) is an antibody-drug conjugate (ADC) targeting cancers that express the CEACAM5 antigen with an average drug-to-antibody ratio (DAR) of 3.8. It links the anti-CEACAM5 monoclonal antibody, tusamitamab, with the cytotoxic agent ravtansine (DM4). This combination allows selective delivery of the chemotherapy drug directly to cancer cells, leading to their destruction. Tusamitamab ravtansine is primarily used to treat solid tumors like non-small cell lung cancer (NSCLC) and colorectal cancer.
Key Features:
- CEACAM5 Targeting: Binds specifically to CEACAM5, a protein found on the surface of certain cancer cells, ensuring targeted delivery of the drug.
- Cytotoxic Agent (Ravtansine/DM4): Ravtansine disrupts microtubules, causing cancer cells to die.
- Linker Technology: The stable linker releases ravtansine inside cancer cells, enhancing precision and minimizing side effects.
Applications:
- Cancer Treatment: Targets and kills CEACAM5-positive cancer cells, particularly in NSCLC and colorectal cancer.
- Targeted Therapy: Delivers ravtansine directly to cancer cells, reducing damage to healthy tissue.
- Monoclonal Antibody Therapy: Provides a targeted, effective treatment for patients with CEACAM5-expressing tumors.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.